


**COVID-19 IMPACT**

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

# RESEARCH REPORT



## Cell Based Assay & High Content Screening Markets

Forecasts by Application. With Executive and Consultant  
Guides and including Customized Forecasting and Analysis.

2021 to 2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

i. Market Guides .....	16
iA. Situation Analysis & COVID-19 Impact .....	17
iB. Guide for Executives and Marketing Staff .....	19
iC. Guide for Investment Analysts and Management Consultants .....	20
1. Introduction and Market Definition .....	21
1.1 What are Cell Based Assays? .....	22
1.2 Clinical Trial Failures.....	25
1.2.1 Immuno-oncology Plays a Leading Role in Cell Based Assays ....	27
1.2.2 Infectious Disease Will Play a Larger Role .....	28
1.3 Market Definition .....	29
1.3.1 Market Size.....	29
1.3.2 Currency .....	29
1.3.3 Years.....	29
1.4 Methodology .....	31
1.4.1 Authors .....	31
1.4.2 Sources.....	31
1.5 U.S. Medical Market and Pharmaceutical Research Spending - Perspective.....	33
1.5.1 U.S. Expenditures for Pharmaceutical Research .....	33

2. Cell Based Assays – Guide to Technology.....	34
2.1 Cell Cultures .....	35
2.1.1 Cell Lines .....	35
2.1.2 Primary Cells .....	43
2.1.3 Stem Cells .....	44
2.1.3.1 iPSC's – The Special Case .....	46
2.2 Cell Assays .....	47
2.3 Cell Viability Assays .....	49
2.3 Cell Proliferation Assays .....	51
2.4 Cytotoxicity Assays .....	52
2.5 Cell Senescence Assays .....	52
2.6 Apoptosis .....	53
2.7 Autophagy .....	54
2.8 Necrosis.....	55
2.9 Oxidative Stress .....	55
2.10 2D vs. 3D .....	57
2.11 Signalling Pathways, GPCR .....	59
2.12 Immune Regulation & Inhibition .....	61
2.13 Reporter Gene Technology .....	62
2.14 CBA Design & Development .....	62
2.15 Cell Based Assays – The Takeaway.....	63
3. Industry Overview .....	65
3.1 Players in a Dynamic Market .....	66

3.1.1 Academic Research Lab .....	67
3.1.2 Contract Research Organization .....	67
3.1.3 Genomic Instrumentation Supplier.....	68
3.1.5 Cell Line and Reagent Supplier .....	68
3.1.6 Pharmaceutical Company .....	68
3.1.7 Audit Body .....	69
3.1.8 Certification Body .....	69
4. Market Trends .....	71
4.1 Factors Driving Growth .....	72
4.1.1 Candidate Growth.....	73
4.1.2 Immuno-oncology .....	73
4.1.3 Genomic Blizzard .....	75
4.1.4 Technology Convergence .....	75
4.1.5 The Insurance Effect .....	76
4.2 Factors Limiting Growth .....	78
4.2.1 CBA Development Challenges .....	78
4.2.2 Instrument Integration .....	79
4.2.3 Protocols .....	79
4.3 Technology Development .....	80
4.3.1 3D Assays .....	80
4.3.2 Automation .....	80
4.3.3 Software .....	81
4.3.4 Primary Cells .....	81

4.3.5 Signalling and Reporter Genes .....	82
4.3.6 The Next Five Years .....	83
5. Cell Based Assays Recent Developments .....	84
5.1 Recent Developments – Importance and How to Use This Section ..	85
5.1.1 Importance of These Developments .....	85
5.1.2 How to Use This Section.....	85
Nanolitre-scale cell assays developed with droplet microarray-mass spec.....	85
Thermo Fisher Scientific Acquires Cell Sorting Technology .....	86
Cellink to Distribute Phasefocus High-Content Cell Imaging Platform....	87
Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance ..	88
Cancer Genetics to Acquire Organoid Startup Stemonix.....	90
Curi Bio Acquires Artificial Intelligence Firm Dana Solutions .....	91
CRISPR Screens Uncover Novel Cancer Therapy Targets .....	92
ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam .....	97
New Transcriptomics Assay Facilitates Compound Screens .....	98
Carta Biosciences Betting on Gene Interaction Mapping .....	102
High-throughput Identifies cancer drug candidates .....	106
Velabs Therapeutics partners with Alytas Therapeutics to develop a novel immune-based therapy for obesity .....	107
InSphero platform selected to test Cyclerion's sGC stimulator technology .....	108
OcellO to provide in vitro research services to Merus.....	110
Charles River Laboratories to acquire Citoxlab .....	111

Reaction Biology Corporation Purchases ProQinase GmbH..... 112

Cisbio extends its assay portfolio for immuno-oncology drug discovery  
..... 114

STEMCELL Technologies Launches Next-Generation Culture System ... 115

Abcam Acquires Calico Biolabs ..... 116

Evotec announces achievement in Celgene alliance utilizing IPSC  
screening ..... 117

Fujifilm Cellular Dynamics Inc. launches iCELL Microglia ..... 118

Cisbio and Excellerate Bioscience partner..... 120

Horizon Discovery extends CRISPR Screening Service to primary human T  
cells..... 121

6. Profiles of Key Cell Based Assay Companies ..... 123

    Abcam..... 124

    Agilent..... 126

    Aurora Instruments Ltd. .... 128

    Axxam ..... 130

    Beckman Coulter Diagnostics ..... 132

    Becton, Dickinson and Company..... 133

    BioIVT ..... 135

    Bio-Rad Laboratories, Inc. .... 137

    BioTek Instruments..... 140

    BioVision, Inc. .... 142

    BMG Labtech..... 144

    Cell Biolabs, Inc..... 145



Cell Signaling Technology, Inc. ....	146
Charles River Laboratories.....	148
Cisbio Bioassays .....	150
Corning, Inc.....	152
Cytovale .....	154
Enzo Life Sciences, Inc.....	155
Eurofins DiscoverX Corporation .....	157
Evotec AG .....	159
Excellerate Bioscience.....	161
Fujifilm Cellular Dynamics International.....	162
Genedata .....	164
Hemogenix.....	165
Horizon Discovery .....	167
Invivogen.....	169
Leica Biosystems .....	171
Lonza Group Ltd.....	173
Luminex Corp.....	175
Merck & Co., Inc.....	177
Miltenyi Biotec.....	179
Molecular Devices .....	180
Nanon .....	182
Ncardia.....	184
New England Biolabs, Inc.....	186

Olympus.....	188
Origene Technologies.....	190
Perkin Elmer .....	191
Promega.....	193
Qiagen Gmbh .....	195
Reaction Biology .....	197
Recursion Pharma .....	198
Roche Diagnostics .....	200
Sartorius.....	202
Sartorius-ForteBio .....	204
Sartorius-IntelliCyt .....	206
Sony Biotechnology .....	207
SPT Labtech.....	209
Stemcells Technologies Canada Inc. ....	211
Tecan .....	213
Thermo Fisher Scientific Inc. ....	215
Vitro Biopharma.....	217
7. Global Market Size .....	219
7.1 Global Market Overview by Country .....	220
7.1.1 Table – Global Market by Country .....	220
7.1.2 Chart - Global Market by Country .....	221
7.2 Global Market by User - Overview .....	222
7.2.1 Table – Global Market by User .....	222

- 7.2.2 Chart – Global Market by User – Base/End Year Comparison ... 223
- 7.2.3 Chart – Global Market by User – Base Year ..... 224
- 7.2.4 Chart – Global Market by User – End Year ..... 225
- 7.2.5 Chart – Global Market by User – Share by Year ..... 226
- 7.3 Global Market by Product Class - Overview ..... 227
  - 7.3.1 Table – Global Market by Product Class ..... 227
  - 7.3.2 Chart – Global Market by Product Class – Base/End Year Comparison ..... 228
  - 7.3.3 Chart – Global Market by Product Class – Base Year ..... 229
  - 7.3.4 Chart – Global Market by Product Class – End Year ..... 230
  - 7.3.5 Chart – Global Market by Product Class – Share by Year ..... 231
- 8. Global Market by User Type ..... 232
  - 8.1 Pharma ..... 233
    - 8.1.1 Table Pharma – by Country ..... 233
    - 8.1.2 Chart - Pharma Growth ..... 234
  - 8.2 Research ..... 235
    - 8.2.1 Table Research – by Country ..... 235
    - 8.2.2 Chart - Research Growth ..... 236
  - 8.3 Industry/Cosmetic ..... 237
    - 8.3.1 Table Industry/Cosmetic – by Country ..... 237
    - 8.3.2 Chart - Industry/Cosmetic Growth ..... 238
- 9. Cell Based Assay by Product Class ..... 239
  - 9.1 Instrument ..... 240

9.1.1 Table Instrument – by Country .....	240
9.1.2 Chart - Instrument Growth.....	241
9.2 Reagent.....	242
9.2.1 Table Reagent – by Country .....	242
9.2.2 Chart - Reagent Growth.....	243
9.3 Services.....	244
9.3.1 Table Services – by Country .....	244
9.3.2 Chart - Services Growth .....	245
9.4 Software.....	246
9.4.1 Table Software – by Country.....	246
9.4.2 Chart - Software Growth .....	247
10. Appendices .....	248
10.1 FDA Cancer Drug Approvals by Year .....	249
10.2 Clinical Trials Started 2010 to 2016.....	250
10.3 Share of Pharma R&D by Country .....	251

## Table of Tables

Table 1 The Large Variety of Cell Lines.....	36
Table 2 Some Common Viability Assays .....	50
Table 3 Oxidative Stress Related Diseases .....	56
Table 4 Important Signalling Pathways .....	59
Table 5 Market Players by Type .....	66
Table 6 Five Factors Driving Growth .....	72
Table 7 Three Factors Limiting Growth .....	78
Table 8 - Global Market by Region.....	220
Table 9 Global Market by User .....	222
Table 10 Global Market by Product Class .....	227
Table 11 Pharma by Country.....	233
Table 12 Research by Country .....	235
Table 13 Industry/Cosmetic by Country.....	237
Table 14 Instrument by Country .....	240
Table 15 Reagent by Country .....	242
Table 16 Services by Country .....	244
Table 17 Software by Country .....	246

## Table of Figures

Figure 1 Reasons for clinical Failure by Phase .....	25
Figure 2 Immunotherapy Clinical Trial Growth .....	28
Figure 3 Pharmaceutical Research Expenditures 2001 to 2017 (\$Billion) ...	33
Figure 4 Oxidative Stress and Free Radical Toxicity .....	56
Figure 5 FDA Cancer Drug Approvals .....	73
Figure 6 Growth rates of Cell Based Assays by Product Class .....	83
Figure 7 Global Market Share Chart .....	221
Figure 8 Global Market by User – Base vs. End Year .....	223
Figure 9 Global Market by User Base Year .....	224
Figure 10 Global Market by User End Year .....	225
Figure 11 User Share by Year .....	226
Figure 12 Global Market by Product Class – Base vs. End Year.....	228
Figure 13 Global Market by Product Class Base Year.....	229
Figure 14 Global Market by Product Class End Year .....	230
Figure 15 Product Class Share by Year.....	231
Figure 16 Pharma Growth .....	234
Figure 17 Research Growth .....	236
Figure 18 Industry/Cosmetic Growth .....	238
Figure 19 Instrument Growth.....	241
Figure 20 Reagent Growth.....	243

Figure 21 Services Growth .....245

Figure 22 Software Growth .....247

Figure 23 FDA Cancer Drug Approvals by Year .....249

Figure 24 Clinical Trials for Immunotherapy by Year.....250

Figure 25 Share of Pharma R&D by Country .....251